Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
CAS Number:
[188039-54-5]
Target:
RSV
* VAT and and shipping costs not included. Errors and price changes excepted